Proactive Investors - Run By Investors For Investors

Clinigen set to snap up Quantum Pharma in £150mln cash-and-shares deal

Clinigen said Quantum is a “sound cultural fit” and the acquisition should provide “immediate financial benefits”
scientist looking through a microscope
The acquisition makes sense given both firms' focus on developing niche medicines

Clinigen Group PLC (LON:CLIN) is closing in on the acquisition of fellow AIM-listed specialty pharma Quantum Pharma PLC (LON:QP.) after the two agreed a £150mln cash-plus-shares deal.

The offer, which has been recommended by Quantum to its shareholders, will see Clinigen pay 37p in cash and 0.0405 new Clinigen shares for each Quantum share.

WATCH: Andrew Hoare on Clinigen's well-timed swoop on Quantum Pharma

Based on Clinigen’s closing price of £11.11 yesterday, that values each Quantum share at 82p and the total offer at £150.3mln.

‘Sound cultural fit’

Clinigen, which began discussions over a possible takeover last month, said Quantum was a “sound cultural fit” and that the acquisition would add “immediate financial benefits”.

The company – which is worth more than £1bn – added that Quantum provides it with a European presence while its international footprint can give Quantum a global reach for its generic licensed products.

WATCH: Quantum Pharma acquisition 'the logical next step' in growth story for Clinigen

The acquisition is also expected to “enhance Clinigen’s position as the global leader in ethical access to unlicensed medicines”.

Merger set to benefit both firms

"The earnings enhancing acquisition of Quantum is an excellent operational and geographical, as well as cultural, fit with Clinigen,” said Clinigen chief executive Shaun Chilton.

“Quantum's UL2L (unlicensed to licensed) capabilities will provide a bridge between our unlicensed and commercial businesses, mirroring our business in the AAA region. Quantum's expertise in this area will enable us to boost our global UL2L ambitions.

READ: Clinigen confirms it is in talks to take over Quantum Pharma

"With the addition of Quantum, we will be in a stronger position to drive our global expansion in the unlicensed and commercial medicine markets."

Quantum boss Chris Rigg added: "The Quantum board is excited by the prospects of the enlarged group and Quantum's role in it."

WATCH: Clinigen achieves a pharma first with EC Cardioxane approval

The acquisition is being funded from existing banking facilities.

Clinigen said it has received irrevocable undertakings – investors who have agreed to sell their shares – from Quantum shareholders representing 19% of the share capital.

View full CLIN profile View Profile

Clinigen Group PLC Timeline

Related Articles

generic pill and bottle shot to denote Alliance's products
August 14 2017
The company has made the transition from a business capitalised at £90mln to company now worth around a quarter of a billion pounds - but has the market at large picked up on (and priced in) the transformation?
boy leaning against chain link fence
We take a look back at the progress made by Summit in the five years since we first spoke to chief executive Glyn Edwards
Novogen: Access latest PPT from Proactive's CEO Sessions
April 13 2017
Dr James Garner talked clinical-stage programs with investors.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use